题名

免疫學在骨質疏鬆症中所扮演的角色：淺談骨免疫學

DOI

10.6666/ClinMed.2017.80.3.100

作者

廖顯宗；蔡長祐

关键词

骨質疏鬆症(osteoporosis) ； 骨免疫學(osteoimmunology) ； 自體免疫疾病(autoimmune disease) ； 破骨細胞(osteoclast, OC) ； 成骨細胞(osteoblast, OB) ； 骨頭細胞(osteocyte)

期刊名称

臨床醫學月刊

卷期/出版年月

80卷3期（2017 / 09 / 29）

页次

542 - 546

内容语文

繁體中文
中文摘要

在老年族群中，骨質疏鬆症是造成骨折及相關共病症最重要的原因。骨質疏鬆的致病機轉是多原因的造成的，一般傳統上的觀念認為是內分泌系統失調為主。然而免疫系統在骨質疏鬆症形成中其實扮演了非常重要的角色。其中包括許多發炎激素會影響骨質吸收及再生，並且進一步闡述了在發炎性關節炎和骨質疏鬆之間相互影響的現象。因此在二十一世紀初，便開始形成了一個學說謂之-骨免疫學(osteo-immunology)。骨免疫學包含了免疫系統(immune system)、破骨細胞(osteoclast, OC)、成骨細胞(osteoblast, OB)、骨頭細胞(osteocyte)、中間影響發炎和傳遞訊息的細胞激素及許多的負責調控成骨細胞及破骨細胞的調節因子。此一學說及相關的研究，正方興未艾的影響著骨質疏鬆症及自體免疫性關節炎發展方向及藥物的研發。
主题分类 醫藥衛生 > 基礎醫學
醫藥衛生 > 社會醫學
参考文献
  1. Arron, JR,Choi, Y(2000).Bone versus immune system.Nature,408,535-536.
  2. D’Amelio, P,Grimaldi, A,Di Bella, S(2008).Estrogen deficiency increases osteoclasto genesis up-regulating T cells activity: a key mechanism in osteoporosis.Bone,43,92-100.
  3. Eghbali-Fatourechi, G,Khosla, S,Sanyal, A(2003).Role of rank ligand in mediating increased bone resorption in early postmenopausal women.J Clin Invest,111,1221-1230.
  4. Hoeppner, LH,Secreto, FJ,Westendorf, JJ(2009).Wnt signaling as a therapeutic target for bone diseases.Expert Opin Ther Targets,13,485-496.
  5. Humphrey, MB,Lanier, LL,Nakamura, MC(2005).Role of ITAM-containing adapter proteins and their receptors in the immune system and bone.Immunol Rev,208,50-65.
  6. Ishimi, Y,Miyaura, C,Jin, CH(1990).IL-6 is produced by osteoblasts and induces bone resorption.J Immunol,145,3297-3303.
  7. Kim, JH,Kim, N(2014).Regulation of NFATc1 in osteoclast differentiation.J Bone Metab,21,233-241.
  8. Kobayashi, K,Takahashi, N,Jimi, E(2000).Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.J Exp Med,191,275-286.
  9. Lee, Y(2013).The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases.BMB Rep,46,479-483.
  10. Pacifici, R,Rifas, L,McCracken, R(1990).The role of interleukin-1 in postmenopausal bone loss.Exp Gerontol,25,309-316.
  11. Pfeilschifter, J,Chenu, C,Bird, A(1989).Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro.J Bone Miner Res,4,113-118.
  12. Pietschmann, P,Grisar, J,Thien, R(2001).Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures.Exp Gerontol,36,1749-1759.
  13. Pietschmann, P,Rauner, M,Sipos, W(2009).Osteoporosis: an age-related and gender-specific disease-a mini-review.Gerontology,55,3-12.
  14. Rachner, TD,Khosla, S,Hofbauer, LC(2011).Osteoporosis: now and the future.Lancet,377,1276-1287.
  15. Rauner, M,Sipos, W,Pietschmann, P(2007).Osteoimmunology.Int Arch Allergy Immunol,143,31-48.
  16. Rauner, M,Sipos, W,Thiele, S(2013).Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities.Int Arch Allergy Immunol,160,114-125.
  17. Roy, B(2013).Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures.World J Diabetes,4,101-113.
  18. Sato, K,Suematsu, A,Okamoto, K(2006).Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.J Exp Med,203,2673-2682.
  19. Soysa, NS,Alles, N,Aoki, K(2012).Osteoclast formation and differentiation: an overview.J Med Dent Sci,59,65-74.
  20. Walsh, MC,Choi, Y(2014).Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond.Front Immunol,5,511.
print cancel